Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer
| Autor: | Pallavi Sachdev, Vicky Makker, Marcia S. Brose, Ana Oaknin, Mark Messing, Antonio Casado Herraez, Emmett V. Schmidt, Daniel E. Stepan, Christopher DiSimone, Margarita Romeo, Raquel Bratos, Carol Aghajanian, Allen Lee Cohn, James W. Mier, Robert Orlowski, Corina E. Dutcus, Jane Wu, Matthew H. Taylor, Robert Shumaker |
|---|---|
| Přispěvatelé: | Institut Català de la Salut, [Makker V, Aghajanian C] Memorial Sloan Kettering Cancer Center, New York, NY, USA. [Taylor MH] Oregon Health & Science University, Portland, OR, USA. [Oaknin A] Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Mier J] Beth Israel Deaconess Medical Center, Boston, MA, USA. [Cohn AL] Rocky Mountain Cancer Center, Denver, CO, USA, Vall d'Hebron Barcelona Hospital Campus |
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
Oncology Cancer Research medicine.medical_specialty Time Factors Pembrolizumab Antibodies Monoclonal Humanized 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Carcinoma Humans In patient Other subheadings::/therapeutic use [Other subheadings] Progression-free survival terapéutica::protocolos clínicos::protocolos antineoplásicos::protocolos de quimioterapia antineoplásica combinada [TÉCNICAS Y EQUIPOS ANALÍTICOS DIAGNÓSTICOS Y TERAPÉUTICOS] Aged Medicaments antineoplàstics - Ús terapèutic - Eficàcia Otros calificadores::/uso terapéutico [Otros calificadores] business.industry Endometrial cancer Phenylurea Compounds Neoplasms::Neoplasms by Site::Urogenital Neoplasms::Genital Neoplasms Female::Uterine Neoplasms::Endometrial Neoplasms [DISEASES] ORIGINAL REPORTS Therapeutics::Clinical Protocols::Antineoplastic Protocols::Antineoplastic Combined Chemotherapy Protocols [ANALYTICAL DIAGNOSTIC AND THERAPEUTIC TECHNIQUES AND EQUIPMENT] Middle Aged medicine.disease Progression-Free Survival Endometrial Neoplasms Clinical trial 030104 developmental biology chemistry 030220 oncology & carcinogenesis Cohort Disease Progression Quinolines Endometri - Càncer Female Microsatellite Instability neoplasias::neoplasias por localización::neoplasias urogenitales::neoplasias de los genitales femeninos::neoplasias uterinas::neoplasias endometriales [ENFERMEDADES] Lenvatinib business Gynecological Cancer |
| Zdroj: | Journal of Clinical Oncology Scientia |
| ISSN: | 1527-7755 |
| Popis: | PURPOSE Patients with advanced endometrial carcinoma have limited treatment options. We report final primary efficacy analysis results for a patient cohort with advanced endometrial carcinoma receiving lenvatinib plus pembrolizumab in an ongoing phase Ib/II study of selected solid tumors. METHODS Patients took lenvatinib 20 mg once daily orally plus pembrolizumab 200 mg intravenously once every 3 weeks, in 3-week cycles. The primary end point was objective response rate (ORR) at 24 weeks (ORRWk24); secondary efficacy end points included duration of response (DOR), progression-free survival (PFS), and overall survival (OS). Tumor assessments were evaluated by investigators per immune-related RECIST. RESULTS At data cutoff, 108 patients with previously treated endometrial carcinoma were enrolled, with a median follow-up of 18.7 months. The ORRWk24 was 38.0% (95% CI, 28.8% to 47.8%). Among subgroups, the ORRWk24 (95% CI) was 63.6% (30.8% to 89.1%) in patients with microsatellite instability (MSI)–high tumors (n = 11) and 36.2% (26.5% to 46.7%) in patients with microsatellite-stable tumors (n = 94). For previously treated patients, regardless of tumor MSI status, the median DOR was 21.2 months (95% CI, 7.6 months to not estimable), median PFS was 7.4 months (95% CI, 5.3 to 8.7 months), and median OS was 16.7 months (15.0 months to not estimable). Grade 3 or 4 treatment-related adverse events occurred in 83/124 (66.9%) patients. CONCLUSION Lenvatinib plus pembrolizumab showed promising antitumor activity in patients with advanced endometrial carcinoma who have experienced disease progression after prior systemic therapy, regardless of tumor MSI status. The combination therapy had a manageable toxicity profile. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|